Literature DB >> 22459269

A defect of CD16-positive monocytes can occur without disease.

Marion Frankenberger1, Arif B Ekici, Matthias W Angstwurm, Harald Hoffmann, Thomas P J Hofer, Irene Heimbeck, Peter Meyer, Peter Lohse, Matthias Wjst, Karl Häussinger, André Reis, Loems Ziegler-Heitbrock.   

Abstract

The CD16-positive monocytes have been first described in 1988 but to date no selective defect in the number of these cells in blood has been reported. We now describe a family in which three of four siblings lack both CD16-positive monocyte subsets, i.e. the nonclassical and the intermediate monocytes. All three had CD16-positive monocytes of 2 cells/μl or less as compared to 52±18 cells/μl in healthy controls. The index case was affected by recurrent pleural effusion and infections and had evidence of an auto-inflammatory condition but no mutation of any of the relevant candidate genes. The other two siblings without CD16-positive monocytes were apparently healthy. There was no defect in serum M-CSF levels and no mutation in the M-CSF and M-CSFR genes. The data indicate that the absence of CD16-positive monocytes in blood does not lead to disease.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459269     DOI: 10.1016/j.imbio.2012.02.013

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  13 in total

1.  Different phenotypes of non-classical monocytes associated with systemic inflammation, endothelial alteration and hepatic compromise in patients with dengue.

Authors:  Juan S Naranjo-Gómez; Jorge Andrés Castillo; Mauricio Rojas; Berta N Restrepo; Francisco J Diaz; Paula A Velilla; Diana Castaño
Journal:  Immunology       Date:  2018-11-08       Impact factor: 7.397

Review 2.  Macrophage biology in development, homeostasis and disease.

Authors:  Thomas A Wynn; Ajay Chawla; Jeffrey W Pollard
Journal:  Nature       Date:  2013-04-25       Impact factor: 49.962

3.  Identification and Characterization of CD300H, a New Member of the Human CD300 Immunoreceptor Family.

Authors:  Kouta Niizuma; Satoko Tahara-Hanaoka; Emiko Noguchi; Akira Shibuya
Journal:  J Biol Chem       Date:  2015-07-28       Impact factor: 5.157

Review 4.  From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation.

Authors:  Paola Italiani; Diana Boraschi
Journal:  Front Immunol       Date:  2014-10-17       Impact factor: 7.561

5.  Effect of CD16a, the surface receptor of Kupffer cells, on the growth of hepatocellular carcinoma cells.

Authors:  Xiu-Yun Li; Lun Wu; Sheng-Wei Li; Wen-Bo Zhou; Meng-Yuan Wang; Guo-Qing Zuo; Chang-An Liu; Xiong Ding
Journal:  Int J Mol Med       Date:  2016-04-12       Impact factor: 4.101

6.  Quantitative whole-cell MALDI-TOF MS fingerprints distinguishes human monocyte sub-populations activated by distinct microbial ligands.

Authors:  Damien Portevin; Valentin Pflüger; Patricia Otieno; René Brunisholz; Guido Vogel; Claudia Daubenberger
Journal:  BMC Biotechnol       Date:  2015-04-11       Impact factor: 2.563

Review 7.  Heterogeneity of Bovine Peripheral Blood Monocytes.

Authors:  Jamal Hussen; Hans-Joachim Schuberth
Journal:  Front Immunol       Date:  2017-12-19       Impact factor: 7.561

Review 8.  Blood Monocytes and Their Subsets: Established Features and Open Questions.

Authors:  Loems Ziegler-Heitbrock
Journal:  Front Immunol       Date:  2015-08-17       Impact factor: 7.561

9.  Phenotypic and functional heterogeneity of bovine blood monocytes.

Authors:  Jamal Hussen; Anna Düvel; Olivier Sandra; David Smith; Iain Martin Sheldon; Peter Zieger; Hans-Joachim Schuberth
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

10.  Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis.

Authors:  Tue W Kragstrup; Babak Jalilian; Malene Hvid; Anders Kjærgaard; René Østgård; Berit Schiøttz-Christensen; Anne G Jurik; William H Robinson; Thomas Vorup-Jensen; Bent Deleuran
Journal:  Arthritis Res Ther       Date:  2014-02-04       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.